SCHEDULE 13G/A: ARCH Venture Funds Update Significant Stake in Beam Therapeutics with Amended SEC Filing
Amended Beneficial Ownership Statement
ARCH Venture Funds and their managing directors have filed an amended Schedule 13G, disclosing their updated beneficial ownership of Beam Therapeutics Inc. common stock, collectively holding approximately 4.5% to 4.6% of the class as of March 31, 2025.
Summary
- The document is an Amendment No. 4 to Schedule 13G, filed by ARCH Venture Funds and their managing directors regarding their beneficial ownership in Beam Therapeutics Inc.
- The reporting persons include ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners IX, LLC, and their managing directors Keith Crandell, Clinton Bybee, and Robert Nelsen.
- As of March 31, 2025, the ARCH entities collectively beneficially own 4,540,132 shares of Beam Therapeutics Inc. common stock, representing 4.5% of the class.
- Individually, Keith Crandell beneficially owns 4,557,862 shares (4.5%), Clinton Bybee owns 4,550,630 shares (4.5%), and Robert Nelsen owns 4,600,747 shares (4.6%). These figures include both shared ownership with the ARCH entities and their respective sole ownership.
- The filing confirms that the aggregate amount beneficially owned by each reporting person is 5 percent or less of the class, consistent with the requirements for a Schedule 13G filing.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Provides updated transparency to shareholders regarding the beneficial ownership stake held by ARCH Venture Funds and their managing directors in Beam Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2020-02-05 | Date of original Form 3 filing referencing the Power of Attorney for Mark McDonnell. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-05-15 | Date of signing the joint filing agreement and the Schedule 13G/A. |
Keywords
Beam Therapeutics Inc., ARCH Venture Fund IX, ARCH Venture Partners, Beneficial Ownership, Schedule 13G/A, SEC Filing, Common Stock, Venture Capital, Institutional Investor, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.